A Louisiana jury pummeled Takeda Pharmaceutical and Eli Lilly & Co. with $9 billion in punitive damages in a liability suit over their blockbuster diabetes drug Actos. It's one for the record books, an amount so far beyond normal that even the victorious lawyers discounted it.
The latest trial over Actos' bladder-cancer risks is set to begin. With thousands of other Actos cases pending against Takeda, the case already was destined to be closely watched. And now, one of the plaintiff's lawyers says he's planning to seek the largest verdict in Nevada history.
The jury has spoken in the latest Actos trial, and the verdict was this: Takeda Pharmaceutical didn't properly flag the risks of its diabetes drug, and Takeda should pay $1.7 million to the family of Diep An, an Actos patient who died of bladder cancer.
For the second time, Takeda Pharmaceuticals is trying to fend off claims that it didn't warn Actos patients about the diabetes drug's links to bladder cancer.
Indian drugmakers are fighting the country's new ban on the diabetes drug pioglitazone, otherwise known as Actos. Regulators suspended sales of the drug last week, citing safety worries, including concerns about an increase in the risk of bladder cancer.
Why now? That's a fair question about India's move to suspend the sale of three drugs, including Takeda Pharmaceuticals' now-off-patent blockbuster, Actos. The country's health ministry also banned Analgin, a decades-old painkiller, and Deanxit, a combination pill for depression.
The prevalence of diabetes is growing globally, and with that the size of the diabetes drug market. But the market has gotten increasingly competitive and increasingly complex. All of the top 10 best-selling drugs in the diabetes category are blockbusters, according to EvaluatePharma. So who makes them? Check out the report >>
The $6.5 million jury verdict in Takeda Pharmaceuticals' first Actos trial didn't last long. Judge Kenneth Freeman tossed out the jury's judgment, saying that plaintiffs' lawyers didn't prove that Jack Cooper's bladder cancer was linked to his use of Actos.
Score one for the plaintiffs in Takeda Pharmaceuticals' Actos litigation. A California jury weighed in against the drugmaker, deciding that Takeda didn't do enough to warn patient Jack Cooper about a heightened risk of bladder cancer.
Actos and its potential links to bladder cancer are now on trial. And already, lawyers have brought out incriminating emails, in which Takeda Pharmaceutical executives discuss damage-control plans. It's the first case pitting a patient with bladder cancer against Japan's Takeda, which built Actos into a $4.5 billion product before safety questions took hold. The company faces at least 3,000 similar claims.